HomeCompareNNCHY vs JNJ

NNCHY vs JNJ: Dividend Comparison 2026

NNCHY yields 3.07% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNCHY wins by $212.60M in total portfolio value
10 years
NNCHY
NNCHY
● Live price
3.07%
Share price
$38.16
Annual div
$1.17
5Y div CAGR
95.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$212.63M
Annual income
$197,266,587.95
Full NNCHY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NNCHY vs JNJ

📍 NNCHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNNCHYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NNCHY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NNCHY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NNCHY
Annual income on $10K today (after 15% tax)
$260.61/yr
After 10yr DRIP, annual income (after tax)
$167,676,599.76/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, NNCHY beats the other by $167,672,613.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NNCHY + JNJ for your $10,000?

NNCHY: 50%JNJ: 50%
100% JNJ50/50100% NNCHY
Portfolio after 10yr
$106.33M
Annual income
$98,635,638.67/yr
Blended yield
92.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NNCHY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
7.9
Piotroski
9/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NNCHY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNNCHYJNJ
Forward yield3.07%2.13%
Annual dividend / share$1.17$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR95.7%28%
Portfolio after 10y$212.63M$30.3K
Annual income after 10y$197,266,587.95$4,689.40
Total dividends collected$211.46M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NNCHY vs JNJ ($10,000, DRIP)

YearNNCHY PortfolioNNCHY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,300$600.01$10,592$272.30+$708.00NNCHY
2$13,331$1,240.06$11,289$357.73+$2.0KNNCHY
3$16,940$2,675.69$12,123$472.89+$4.8KNNCHY
4$24,344$6,218.56$13,141$629.86+$11.2KNNCHY
5$42,393$16,344.90$14,408$846.81+$28.0KNNCHY
6$97,419$52,058.22$16,021$1,151.60+$81.4KNNCHY
7$323,036$218,797.85$18,122$1,588.22+$304.9KNNCHY
8$1,672,608$1,326,958.99$20,930$2,228.20+$1.65MNNCHY
9$14,355,990$12,566,300.15$24,792$3,191.91+$14.33MNNCHY
10$212,627,498$197,266,587.95$30,274$4,689.40+$212.60MNNCHY

NNCHY vs JNJ: Complete Analysis 2026

NNCHYStock

Nissan Chemical Corporation engages in the chemicals, performance materials, agricultural chemicals, and pharmaceuticals businesses in Japan and internationally. Its chemical products include MELAMINE, an adhesive agent; high purity chemicals; AdBlue, an urea solution; ammonia, sulfuric, and nitric acid; TEPIC, an epoxy compound; Melamine Cyanurate, a salt of melamine and iso cyanuric acid; Nissan Reishi, a health food; phenylphosphonic acid; HI-LITE, a chlorinated isocyanulate; OPTBEADS, a melamine-formaldehyde resin and silica; and FINEOXOCOL, a saturated fatty alcohol and acid. The company also offers performance materials comprising display, semiconductor, and inorganic materials; agricultural chemicals, such as herbicides, insecticides, fungicides, etc. for use on agricultural land, as well as in golf courses and parks; and drug substances for antiparasite drugs for animals. In addition, it provides pharmaceutical products, such as LIVALO, a cholesterol reduction agent; LANDEL and FINTE, a dual type calcium antagonist that blocks calcium channels; and custom manufacturing and process researching services for pharmaceutical ingredients. Further, the company develops healthcare, information and communication materials, and environmental and energy materials. The company was formerly known as Nissan Chemical Industries, Ltd. and changed its name to Nissan Chemical Corporation in July 2018. Nissan Chemical Corporation was founded in 1887 and is headquartered in Tokyo, Japan.

Full NNCHY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NNCHY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NNCHY vs SCHDNNCHY vs JEPINNCHY vs ONNCHY vs KONNCHY vs MAINNNCHY vs ABBVNNCHY vs MRKNNCHY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.